Axel Åkerblom

Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial

Stefan James, Axel Åkerblom, Christopher P. Cannon et al. · American Heart Journal · 2009 · 402 citations

Medicine, Pharmacology, Pharmacotherapy +17

Population Trends in Percutaneous Coronary Intervention

Marieke L. Fokkema, Stefan James, Per Albertsson et al. · Journal of the American College of Cardiology · 2013 · 170 citations

Medicine, Cardiology, Clinical Cardiology +12

Effect of genetic variations on ticagrelor plasma levels and clinical outcomes

Christoph Varenhorst, Niclas Eriksson, Åsa Johansson et al. · European Heart Journal · 2015 · 147 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study

Stephen Zewinger, Marcus E. Kleber, Vinicius Tragante et al. · The Lancet Diabetes & Endocrinology · 2017 · 106 citations · Full text

Medicine, Cardiology, Genetics +15

Eptifibatide Is Noninferior to Abciximab in Primary Percutaneous Coronary Intervention

Axel Åkerblom, Stefan James, Michail Koutouzis et al. · Journal of the American College of Cardiology · 2010 · 67 citations

Medicine, Cardiology, Pharmacotherapy +12